Hana Pharm

293480 · KOSPI · ₩293480 · 하나제약

₩8,170▼ ₩40 (0.49%)End-of-day · Oct 27, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩25,373

vs the current price (₩8,170)

Enterprise value
₩509B
Equity value
₩451B
WACC
6.4%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Why the model and the price differ

The model is 211% away from today's price. A gap this size usually means the market expects something the past figures don't show yet, or the model leaves something out. What we can see:

  • To match today's price of ₩8,170, the model needs an operating margin of 5.6% every year (it uses 12.4%).
  • Or revenue growth −24.6 points a year higher than assumed in each of the 5 years.
  • Today's P/E is 12.4× against a typical 10.9× over the last 10 years.

Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.

Bear / Base / Bull

Bear
₩13,976
+71.1%
Base
₩25,373
+210.6%
Bull
₩46,248
+466.1%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (12.4%).

Revenue growth

  • 4.3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (4.3% a year, annual reports), fading to 3% by year 5.

  • 4%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (4.3% a year, annual reports), fading to 3% by year 5.

  • 3.7%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (4.3% a year, annual reports), fading to 3% by year 5.

  • 3.3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (4.3% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (4.3% a year, annual reports), fading to 3% by year 5.

Business

  • 12.4%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 0.5%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).

  • 0.7%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 31.1%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.03%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-27.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.08, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.53%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩247B
Net debt (borrowings and leases − cash and deposits)
₩58B
+ Stakes and investments
₩48M
Associates, long-term financial assets and deposits (book value)
Shares
17,772,946
Share price
₩8,170
Market cap
₩145B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2023FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩224B₩225B₩240B₩258B₩268B₩278B₩287B₩296B
Growth6.5%0.4%6.3%4.3%4.0%3.7%3.3%3.0%
EBIT₩27B₩25B₩26B₩32B₩33B₩34B₩36B₩37B
EBIT margin12.0%11.2%10.8%12.4%12.4%12.4%12.4%12.4%
After-tax EBIT₩20B₩18B₩19B₩23B₩24B₩25B₩26B₩27B
+ Depreciation———₩1.3B₩1.3B₩1.4B₩1.4B₩1.5B
− Capital spending₩1.5B——₩1.8B₩1.9B₩1.9B₩2B₩2.1B
− Working capital₩12B₩842M₩8.2B₩3.3B₩3.2B₩3.1B₩2.9B₩2.7B
Free cash flow———₩19B₩20B₩21B₩22B₩23B
Discount factor———0.9400.8840.8300.7810.734
Present value———₩18B₩18B₩18B₩17B₩17B

Terminal value ₩572B, worth ₩420B today: 83% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Cross-check: what the market has paid before

For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:

LowTypicalHigh
Price / book (book value ₩18,666 a share)Now 0.44×₩9,8850.53×₩15,8720.85×₩24,9351.34×
Price / earnings (last 12 months: ₩658 a share)Now 12.4×₩6,1939.41×₩7,16210.9×₩12,11618.4×

Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
5.4%₩27,332₩30,229₩33,975₩39,011₩46,150
5.9%₩24,122₩26,338₩29,120₩32,717₩37,554
6.4%₩21,509₩23,245₩25,373₩28,043₩31,496
6.9%₩19,341₩20,728₩22,394₩24,436₩26,998
7.4%₩17,515₩18,639₩19,969₩21,567₩23,526

Now (TTM)

Market cap
₩145B
Enterprise value
₩199B
P/E
12.4×
P/B
0.4×
P/S
0.6×
EV/EBITDA
—
Dividend yield
3.2%

Over time (at each year end)

20252024202320222021
Price₩11,220₩10,900₩13,950₩18,250₩20,150
Market cap₩199B₩194B₩248B₩324B₩358B
P/E22.7×9.1×11.1×13.3×12.8×
P/B0.6×0.6×0.9×1.2×1.4×
P/S0.8×0.9×1.1×1.5×1.8×
EV/EBITDA—————
Dividend yield2.3%4.7%———

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
Hana Pharm12.4×0.4×0.6×—3.2%
Samsung Biologics32.1×7.6×14.0×—0.0%
Celltrion27.8×2.4×8.9×—0.0%
Alteogen78.8×28.4×59.9×—0.1%
Yuhan24.8×2.5×2.6×32.5×0.8%
SK biopharmaceuticals14.6×5.7×6.8×—0.0%
HLB—15.4×54.6×—0.0%
Similar companies (median)27.8×6.7×11.5×32.5×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: Hana Pharm / 하나제약 / 293480 / KRX:293480

Source: KRX statistical information